Treatment

Phase IIa exploratory trial of T3D-959 in mild-moderate Alzheimer’s disease

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Preliminary results from the Phase II PIONEER trial of T3D-959 in mild-moderate Alzheimer’s disease

Is amyloid lowering still a valid approach in Alzheimer’s disease?

EXERT results: exercise shown to stall cognitive decline in patients with mild cognitive impairment

Developing APOE-targeted epigenome therapy for the treatment of Alzheimer’s disease

Investigating aerobic exercise and cognition in older adults

Design of the Phase III EXERT trial of aerobic exercise in mild cognitive impairment

Therapeutic targeting of TREM2 in Alzheimer’s disease

The importance of vascular disease in the management of dementia

Updates on neuromodulation for Alzheimer’s disease

Potential of anti-amyloid drugs for treating Alzheimer’s disease

Long-term clinical results of TPS in Alzheimer’s disease

Ethical considerations when investigating the causes of mild cognitive impairment

Important developments in dementia: biomarkers & clinical trials

Targeting β-amyloid and tau in Alzheimer’s disease